Assessment of Effects of Investigational TAK‐931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors.

Autor: Zhou, Xiaofei1 (AUTHOR), Diderichsen, Paul Matthias2 (AUTHOR), Gupta, Neeraj1 (AUTHOR) neeraj.gupta@takeda.com
Zdroj: Clinical Pharmacology in Drug Development. Jun2022, Vol. 11 Issue 6, p770-779. 10p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje